Literature DB >> 8450047

Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

L Ferradini1, A Mackensen, C Genevée, J Bosq, P Duvillard, M F Avril, T Hercend.   

Abstract

Malignant melanomas are often infiltrated by T lymphocytes. It is postulated that the presence of tumor-infiltrating lymphocytes (TIL) reflects ongoing immune responses against transformed cells. Such "responses" appear generally inefficient with the potential exception of infrequent clinical situations characterized by spontaneous tumor regression. We have characterized here the molecular structure of the T cell receptor beta chain expressed by TILs in a case of regressive melanoma. Advantage was taken of the PCR technology to study T lymphocytes directly without cell culture. Experimentally validated V beta subfamily specific primers were used to evaluate the V beta usage in TILs and control samples. Our results reveal that clonal T cell populations, precisely defined by their V-D-J junctional sequences, are amplified at the tumor site. The existence of such local antigen-driven selections support the hypothesis that antitumor responses may indeed take place in regressive melanoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450047      PMCID: PMC288075          DOI: 10.1172/JCI116278

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

Review 1.  T-cell antigen receptor genes and T-cell recognition.

Authors:  M M Davis; P J Bjorkman
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  Immunochemical proof that a novel rearranging gene encodes the T cell receptor delta subunit.

Authors:  H Band; F Hochstenbach; J McLean; S Hata; M S Krangel; M B Brenner
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

4.  Spontaneous regression of melanoma.

Authors:  V J McGovern
Journal:  Pathology       Date:  1975-04       Impact factor: 5.306

5.  T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes.

Authors:  H Blüthmann; P Kisielow; Y Uematsu; M Malissen; P Krimpenfort; A Berns; H von Boehmer; M Steinmetz
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

6.  Thin malignant melanomas with regression and metastases.

Authors:  S G Ronan; A M Eng; H A Briele; N N Shioura; T K Das Gupta
Journal:  Arch Dermatol       Date:  1987-10

7.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

8.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  In transgenic mice the introduced functional T cell receptor beta gene prevents expression of endogenous beta genes.

Authors:  Y Uematsu; S Ryser; Z Dembić; P Borgulya; P Krimpenfort; A Berns; H von Boehmer; M Steinmetz
Journal:  Cell       Date:  1988-03-25       Impact factor: 41.582

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  43 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

3.  In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.

Authors:  Y Sun; P Möller; C Berking; E M Schlüpen; M Volkenandt; D Schadendorf
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

Review 4.  Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?

Authors:  Nayoung Lee; Steven R Barthel; Tobias Schatton
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

5.  NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.

Authors:  Meriem Messaoudene; Giulia Fregni; David Enot; Nicolas Jacquelot; Emmanuelle Neves; Nathalie Germaud; Henri Jean Garchon; Wahid Boukouaci; Ryad Tamouza; Johan Chanal; Marie-Françoise Avril; Antoine Toubert; Laurence Zitvogel; Sylvie Rusakiewicz; Anne Caignard
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

6.  Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Authors:  Mariana Rodríguez Zubieta; David Furman; Marcela Barrio; Alicia Inés Bravo; Enzo Domenichini; José Mordoh
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 7.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Normalization Cancer Immunotherapy for Melanoma.

Authors:  Matthew D Vesely; Lieping Chen
Journal:  J Invest Dermatol       Date:  2020-02-22       Impact factor: 8.551

9.  Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.

Authors:  Claude Lalou; Nathalie Scamuffa; Samia Mourah; Francois Plassa; Marie-Pierre Podgorniak; Nadem Soufir; Nicolas Dumaz; Fabien Calvo; Nicole Basset-Seguin; Abdel-Majid Khatib
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

10.  Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.

Authors:  Wolfram Osen; Sabine Soltek; Mingxia Song; Barbara Leuchs; Julia Steitz; Thomas Tüting; Stefan B Eichmüller; Xuan-Duc Nguyen; Dirk Schadendorf; Annette Paschen
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.